FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4312177316> ?p ?o ?g. }

• W4312177316 endingPage "29" @default.
• W4312177316 startingPage "21" @default.
• W4312177316 abstract "Introduction . PARP inhibitors demonstrated high efficacy in BRCA1/2-associated Her2-negative metastatic breast cancer (BC). They were included in the current standard chemotherapy regimen and recognized as a priority option for the treatment of such tumours following the results of clinical studies. Aim . Review the experience with talazoparib (Talzenna) in the real-world clinical practice of 6 medical centers in Russia. Materials and methods . The review included data from 29 patients with HER2-negative metastatic breast cancer associated with a gBRCA mutation, who have been receiving talazoparib therapy in 6 medical centers of Russia since April 2021. Talazoparib was given at the standard dose 1 mg once daily, the dose was reduced, if any adverse event developed. Results . The median age of the patients was 50 years. 23 patients had a BRCA1 mutation, 5 patients had a BRCA2 mutation and one of the patients had a PALB2 mutation. Prior to starting talazoparib therapy, patients had received up to 9 lines of therapy for metastatic disease, the median was 1 line. The median follow-up period at that time was only 4.6 months. The median recurrence-free survival (RFS) was not reached. Progression was observed in 10 patients with a treatment period of 1 to 7.5 months, 19 patients continued to receive PARP inhibitor therapy without signs of disease progression, with a treatment period of 2 to 18 months. The objective response rate (ORR) was 57.2%, the clinical efficacy was confirmed in 85.7% of cases. The subgroup analysis showed that the lowest efficacy of therapy was reported in the group of patients, who had received prior therapy with platinum-based drugs, the median progression-free time (mPFT) was 4.5 months. (95% CI: 1.79-9.2). While for patients who had not received the prior platinum drug regimens, the median was not reached. Haematologic toxicities were common adverse events (AEs) for the talazoparib therapy, which were reported in 34.5% of cases. Transfusions of blood components were required in 3 patients, one of them required them repeatedly. All dose modifications were due to hematological toxicities. 7 patients (24.1%) required a dose reduction and 3 patients (10.3%) - repeated dose reduction. Conclusions . Testing for BRCA1/2 mutations in Her2-negative mBC should be a mandatory diagnostic procedure. Talazoparib therapy is an effective and safe treatment option for patients with gBRCAmut HER2-mBC." @default.
• W4312177316 created "2023-01-04" @default.
• W4312177316 creator A5008965511 @default.
• W4312177316 creator A5021130930 @default.
• W4312177316 creator A5022911908 @default.
• W4312177316 creator A5029205709 @default.
• W4312177316 creator A5036016408 @default.
• W4312177316 creator A5037488219 @default.
• W4312177316 creator A5044992418 @default.
• W4312177316 creator A5053341304 @default.
• W4312177316 creator A5057094897 @default.
• W4312177316 creator A5060597318 @default.
• W4312177316 creator A5080127289 @default.
• W4312177316 creator A5081116067 @default.
• W4312177316 creator A5081523614 @default.
• W4312177316 creator A5083738393 @default.
• W4312177316 date "2022-12-06" @default.
• W4312177316 modified "2023-09-25" @default.
• W4312177316 title "Therapy of BRCA-associated metastatic breast cancer. Efficacy and safety of talazoparib in the real-world clinical practice" @default.
• W4312177316 cites W1999197880 @default.
• W4312177316 cites W2058139855 @default.
• W4312177316 cites W2166702788 @default.
• W4312177316 cites W2298876126 @default.
• W4312177316 cites W2403389346 @default.
• W4312177316 cites W2592941899 @default.
• W4312177316 cites W2604876648 @default.
• W4312177316 cites W2621271973 @default.
• W4312177316 cites W2627871710 @default.
• W4312177316 cites W2796194059 @default.
• W4312177316 cites W2808864948 @default.
• W4312177316 cites W2886477543 @default.
• W4312177316 cites W2887648164 @default.
• W4312177316 cites W2898606077 @default.
• W4312177316 cites W2969222240 @default.
• W4312177316 cites W2988654884 @default.
• W4312177316 cites W2997880320 @default.
• W4312177316 cites W3010605760 @default.
• W4312177316 cites W3129192144 @default.
• W4312177316 cites W3170605659 @default.
• W4312177316 cites W3202115015 @default.
• W4312177316 cites W4224327237 @default.
• W4312177316 cites W4294862258 @default.
• W4312177316 doi "https://doi.org/10.21518/2079-701x-2022-16-22-21-29" @default.
• W4312177316 hasPublicationYear "2022" @default.
• W4312177316 type Work @default.
• W4312177316 citedByCount "0" @default.
• W4312177316 crossrefType "journal-article" @default.
• W4312177316 hasAuthorship W4312177316A5008965511 @default.
• W4312177316 hasAuthorship W4312177316A5021130930 @default.
• W4312177316 hasAuthorship W4312177316A5022911908 @default.
• W4312177316 hasAuthorship W4312177316A5029205709 @default.
• W4312177316 hasAuthorship W4312177316A5036016408 @default.
• W4312177316 hasAuthorship W4312177316A5037488219 @default.
• W4312177316 hasAuthorship W4312177316A5044992418 @default.
• W4312177316 hasAuthorship W4312177316A5053341304 @default.
• W4312177316 hasAuthorship W4312177316A5057094897 @default.
• W4312177316 hasAuthorship W4312177316A5060597318 @default.
• W4312177316 hasAuthorship W4312177316A5080127289 @default.
• W4312177316 hasAuthorship W4312177316A5081116067 @default.
• W4312177316 hasAuthorship W4312177316A5081523614 @default.
• W4312177316 hasAuthorship W4312177316A5083738393 @default.
• W4312177316 hasBestOaLocation W43121773161 @default.
• W4312177316 hasConcept C104317684 @default.
• W4312177316 hasConcept C121608353 @default.
• W4312177316 hasConcept C126322002 @default.
• W4312177316 hasConcept C141071460 @default.
• W4312177316 hasConcept C143998085 @default.
• W4312177316 hasConcept C182979987 @default.
• W4312177316 hasConcept C185592680 @default.
• W4312177316 hasConcept C197934379 @default.
• W4312177316 hasConcept C2775930923 @default.
• W4312177316 hasConcept C2776694085 @default.
• W4312177316 hasConcept C2779134260 @default.
• W4312177316 hasConcept C2779138821 @default.
• W4312177316 hasConcept C2780194787 @default.
• W4312177316 hasConcept C2781413609 @default.
• W4312177316 hasConcept C530470458 @default.
• W4312177316 hasConcept C55493867 @default.
• W4312177316 hasConcept C71924100 @default.
• W4312177316 hasConcept C82381507 @default.
• W4312177316 hasConceptScore W4312177316C104317684 @default.
• W4312177316 hasConceptScore W4312177316C121608353 @default.
• W4312177316 hasConceptScore W4312177316C126322002 @default.
• W4312177316 hasConceptScore W4312177316C141071460 @default.
• W4312177316 hasConceptScore W4312177316C143998085 @default.
• W4312177316 hasConceptScore W4312177316C182979987 @default.
• W4312177316 hasConceptScore W4312177316C185592680 @default.
• W4312177316 hasConceptScore W4312177316C197934379 @default.
• W4312177316 hasConceptScore W4312177316C2775930923 @default.
• W4312177316 hasConceptScore W4312177316C2776694085 @default.
• W4312177316 hasConceptScore W4312177316C2779134260 @default.
• W4312177316 hasConceptScore W4312177316C2779138821 @default.
• W4312177316 hasConceptScore W4312177316C2780194787 @default.
• W4312177316 hasConceptScore W4312177316C2781413609 @default.
• W4312177316 hasConceptScore W4312177316C530470458 @default.
• W4312177316 hasConceptScore W4312177316C55493867 @default.
• W4312177316 hasConceptScore W4312177316C71924100 @default.
• W4312177316 hasConceptScore W4312177316C82381507 @default.

• next